What’s the Journavx® Buzz About?

It’s only been a few months since the FDA approved Journavx^®—a novel, non-opioid treatment for acute pain—and already patients are asking for it by name. Approved in January 2025, Journavx is making waves among physicians and patients alike for its potential to address moderate-to-severe acute pain without the risk of addiction.